Prognostic significance of p53 protein expression in early gastric cancer

Pathology and Oncology Research

Volumn 17, Issue 2, 2011, Pages 349-355

  Gonçalves, Andrea Rodrigues ^a,b   Carneiro, Antonio Jose Vasconcellos ^a   Martins, Ivanir ^b   De Faria, Paulo Antonio Silvestre ^b   Ferreira, Maria Aparecida ^b   De Mello, Eduardo Linhares Riello ^b   Fogaça, Homero Soares ^a   Elia, Celeste Carvalho Siqueira ^a   De Souza, Heitor Siffert Pereira ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Early gastric cancer; p53; Prognosis

Indexed keywords

PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENDER; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; P53 GENE; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STOMACH CANCER; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADENOCARCINOMA; CELL DIFFERENTIATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80051669139     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-010-9333-z     Document Type: Article

References (50)

1. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA (2000) Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29:645-654 (Pubitemid 30612230)
2. Boussioutas A, Taupin D (2001) Towards a molecular approach to gastric cancer management. Intern Med J 31:296-303 (Pubitemid 32734933)
3. Shah MA (2006) Gastric cancer: an update. Curr Oncol Rep 8:183-191
4. Field K, Michael M, Leong T (2008) Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 68:299-317 (Pubitemid 351227347)
5. Kaibara N, Sumi K, Yonekawa M, Ohta M, Makino M, Kimura O, Nishidoi H, Koga S (1990) Does extensive dissection of lymph nodes improve the results of surgical treatment of gastric cancer? Am J Surg 159:218-221 (Pubitemid 20057922)
6. Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, Sugimachi K (2000) Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery 128:408-416
7. Forman D, Burley VJ (2006) Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 20:633-649 (Pubitemid 44391336)
8. Anderson C, Nijagal A, Kim J (2006) Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther 10:345-352 (Pubitemid 44927048)
9. Smith MG, Hold GL, Tahara E, El-Omar EM (2006) Cellular and molecular aspects of gastric cancer. World J Gastroenterol 12:2979-2990 (Pubitemid 43811073)
10. Prives C, Hall PA (1999) The p53 pathway. J Pathol 187:112-126 (Pubitemid 29009841)
11. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878 (Pubitemid 24289415)
12. Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M et al (1998) IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualization tools. Nucleic Acids Res 26:205-213 (Pubitemid 28291534)
13. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311
14. Hollstein M, Sidransky D, Vogelstein B, Harris C (1991) p53 mutations in human cancers. Science 253:49-53 (Pubitemid 21917115)
15. Lane DP (1994) The regulation of p53 function: Steiner award lecture. Int J Cancer 57:623-627 (Pubitemid 24201349)
16. Starzynska T, Bromley M, Ghosh A, Stern PL (1992) Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 66:558-562
17. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, Sugimachi K (1993) Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 67:589-593 (Pubitemid 23077658)
18. Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, Lane DP, Cuschieri A (1994) The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 69:943-946 (Pubitemid 24140680)
19. Motojima K, Furui J, Kohara N, Ito T, Kanematsu T (1994) Expression of p53 protein in gastric carcinomas is not independently prognostic. Surgery 116:890-895 (Pubitemid 24347199)
20. Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G (1995) The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 76:720-726
21. Bataille F, Rümmele P, Dietmaier W, Gaag D, Klebl F, Reichle A, Wild P, Hofstädter F, Hartmann A (2003) Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol Pathol 56:286-92 (Pubitemid 37243921)
22. Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, Kuroshima K, Aikou T (1999) Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. Oncology 57:131-137 (Pubitemid 29385491)
23. Lauren P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31-49
24. Montesano R, Hollstein M, Hainaut P (1996) Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer 69:225-235 (Pubitemid 26233303)
25. Soussi T, Beroud C (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1:233-240 (Pubitemid 33741898)
26. Carson DA, Lois A (1995) Cancer progression and p53. Lancet 346:1009-1011
27. Chang F, Syrjänen S, Syrjänen K (1995) Implications of the p53 tumorsuppressor gene in clinical oncology. J Clin Oncol 13:1009-1022
28. Yokozaki H, Kuniyasu H, Kitadai Y, Nishimura K, Todo H, Ayhan A, Yasui W, Ito H, Tahara E (1992) p53 point mutations in primary human gastric carcinomas. J Cancer Res Clin Oncol 119:67-70
29. Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S (1993) p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 54:759-764 (Pubitemid 23228606)
30. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR (1998) The p53 network. J Biol Chem 273:1-4 (Pubitemid 28042164)
31. Hall PA, Lane DP (1994) p53 in tumor pathology: can we trust immunohistochemistry?-Revisited! J Pathol 72:1-4 (Pubitemid 24074994)
32. Gannon JV, Greaves R, Iggo R, Lane DP (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595-1602
33. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351:453-456 (Pubitemid 21896613)
34. Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E, Kakeji Y, Sugimachi K (1999) Prognostic value of p53 protein expression for patients with gastric cancer-a multivariate analysis. Br J Cancer 79:1255-1261 (Pubitemid 29087907)
35. Ming SC (1998) Cellular and molecular pathology of gastric carcinoma and precursor lesions: A critical review. Gastric Cancer 1:31-50
36. Wang JY, Lin SR, Hsieh JS, Hsu CH, Huang YS, Huang TJ (2001) Mutations of p53 gene in gastric carcinoma in Taiwan. Anticancer Res 21:513-520
37. Tahara E, Semba S, Tahara H (1996) Molecular biological observations in gastric cancer. Semin Oncol 23:307-315 (Pubitemid 26187730)
38. Wu MS, Shun CT, Lee WC, Chen CJ, Wang HP, Lee WJ, Sheu JC, Lin JT (1998) Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer. Br J Cancer 78:971-973
39. Wu MS, Shun CT, Wu CC, Hsu TY, Lin MT, Chang MC, Wang HP, Lin JT (2000) Epstein-Barr virus-associated gastric carcinomas: relation to H. pylori infection and genetic alterations. Gastroenterology 118:1031-1038
40. Correa P (1992) Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52:6735-6740 (Pubitemid 23006271)
41. Kodama M, Fujioka T, Murakami K, Okimoto T, Sato R, Watanabe K, Nasu M (2005) Eradication of Helicobacter pylori reduced the immunohistochemical detection of p53 and MDM2 in gastric mucosa. J Gastroenterol Hepatol 20:941-946 (Pubitemid 40897179)
42. Morgan C, Jenkins G J S, Ashton T, Griffiths AP, Baxter JN, Parry EM, Parry JM (2003) Detection of p53 mutations in precancerous gastric tissue. Br J Cancer 89:1314-1319 (Pubitemid 37363423)
43. Kodama M, Murakami K, Okimoto T, Sato R, Watanabe K, Fujioka T (2007) Expression of mutant type-p53 products in H pylori-associated chronic gastritis. World J Gastroenterol 13:1541-1546 (Pubitemid 46672662)
44. Li JH, Shi XZ, Lv S, Liu M, Xu GW (2005) Effect of helicobacter pylori infection on p53 expression of gastric mucosa and adenocarcinoma with microsatellite instability. World J Gastroenterol 11:4363-4366 (Pubitemid 41093955)
45. Maehara Y, Kakeji Y, Oda S, Baba H, Sugimachi K (2001) Tumor growth patterns and biological characteristics of early gastric carcinoma. Oncology 61:102-112 (Pubitemid 32786203)
46. Noda H, Maehara Y, Irie K, Kakeji Y, Yonemura T, Sugimachi K (2001) Growth pattern and expressions of cell cycle regulator proteins p53 and p21 WAF1/CIP1 in early gastric carcinoma. Cancer 92:1828-1835 (Pubitemid 32952501)
47. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC (1992) The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735-738
48. Hamilton JP, Meltzer SJ (2006) A Review of the Genomics of Gastric Cancer. Clin Gastroenterol Hepatol 4:416-425
49. Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H (2004) Coexistence of HER2 overexpression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6:R24-30
50. Lu C-D, Altieri DC, Tanigawa N (1998) Expression of A Novel Antiapoptosis Gene, Survivin, Correlated with Tumor Cell Apoptosis and p53 Accumulation in Gastric Carcinomas. Cancer Res 58:1808-1812 (Pubitemid 28217451)